AP
NUVL

Antipodes Partners’s Nuvalent NUVL Stock Holding History

Antipodes Partners’s Portfolio NUVL Stock Details NUVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-275
Closed -$28.2K – 145
2026
Q1 		$28.2K Sell
275
-116
-30% -$11.8K ﹤0.01% 116
2025
Q4 		$39.3K Hold
391
– – ﹤0.01% 112
2025
Q3 		$33.8K Sell
391
-88
-18% -$6.96K ﹤0.01% 102
2025
Q2 		$36.5K Sell
479
-61
-11% -$4.46K ﹤0.01% 93
2025
Q1 		$38.3K Buy
+540
New +$42.2K ﹤0.01% 85

Other funds holding NUVL

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Antipodes Partners's NUVL Position: Q2 2026 in Review

Antipodes Partners sold out of Nuvalent (NUVL) in Q2 2026, closing a stake of 275 shares — an estimated $28.2K sold.

Antipodes Partners first reported a position in NUVL in Q1 2025 and held it in 5 quarters. The position peaked at $39.3K in Q4 2025. 293 funds tracked by Wall St. Rank hold NUVL as of Q2 2026.

  • Antipodes Partners reported no remaining Nuvalent position as of Q2 2026 after selling out during the quarter.
  • Antipodes Partners sold 275 Nuvalent shares in Q2 2026, an estimated $28.2K.
  • Antipodes Partners first reported a position in Nuvalent in Q1 2025 and held it in 5 quarters.
  • Antipodes Partners's Nuvalent position peaked at $39.3K in Q4 2025.
  • 293 funds tracked by Wall St. Rank held Nuvalent as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.